BR112018012310A2 - sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina - Google Patents

sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina

Info

Publication number
BR112018012310A2
BR112018012310A2 BR112018012310A BR112018012310A BR112018012310A2 BR 112018012310 A2 BR112018012310 A2 BR 112018012310A2 BR 112018012310 A BR112018012310 A BR 112018012310A BR 112018012310 A BR112018012310 A BR 112018012310A BR 112018012310 A2 BR112018012310 A2 BR 112018012310A2
Authority
BR
Brazil
Prior art keywords
saccharide
conjugate
vaccine
synthesis method
formula
Prior art date
Application number
BR112018012310A
Other languages
English (en)
Inventor
Anish Chakkumkal
Lebev Pereira Claney
EMMADI Madhu
Khan Naeem
H Seeberger Peter
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15200729.0A external-priority patent/EP3181148A1/en
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BR112018012310A2 publication Critical patent/BR112018012310A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)

Abstract

a presente invenção diz respeito a um sacarídeo sintético de fórmula geral (i) que é relacionado a polissacarídeo capsular streptococcus pneumoniae sorotipo 2, um conjugado deste e a utilização de dito sacarídeo e conjugado para obtenção de uma resposta imune protetora em um hospedeiro humano e/ou animal. adicionalmente, o sacarídeo sintético de fórmula geral (i) é útil como marcador em ensaios imunológicos para detecção de anticorpos contra a bactéria streptococcus pneumoniae tipo 2.
BR112018012310A 2015-12-17 2016-12-16 sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina BR112018012310A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15200729.0A EP3181148A1 (en) 2015-12-17 2015-12-17 Synthetic vaccines against streptococcus pneumoniae serotype 2
EP16167505 2016-04-28
PCT/EP2016/081586 WO2017103211A1 (en) 2015-12-17 2016-12-16 Synthetic vaccines against streptococcus pneumoniae serotype 2

Publications (1)

Publication Number Publication Date
BR112018012310A2 true BR112018012310A2 (pt) 2018-12-04

Family

ID=57543058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012310A BR112018012310A2 (pt) 2015-12-17 2016-12-16 sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina

Country Status (13)

Country Link
US (1) US10864261B2 (pt)
EP (1) EP3331556B8 (pt)
JP (1) JP6630440B2 (pt)
KR (1) KR20180091921A (pt)
CN (1) CN108367059B (pt)
AU (1) AU2016372547A1 (pt)
BR (1) BR112018012310A2 (pt)
HK (1) HK1256630B (pt)
IL (1) IL259289B (pt)
MX (1) MX371087B (pt)
PH (1) PH12018501205A1 (pt)
SG (1) SG11201803881RA (pt)
WO (1) WO2017103211A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016091399A1 (en) * 2014-12-12 2016-06-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against streptococcus pneumoniae serotype 4
BR112018012310A2 (pt) 2015-12-17 2018-12-04 Max Planck Gesellschaft sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2022106703A1 (en) * 2020-11-20 2022-05-27 Institut Pasteur Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI1014494A2 (pt) * 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
HRP20221438T1 (hr) * 2012-12-20 2023-02-03 Pfizer Inc. Postupak glikokonjugiranja
JP6524218B2 (ja) * 2014-09-26 2019-06-05 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー 肺炎連鎖球菌血清型８に対するワクチン
WO2016091399A1 (en) * 2014-12-12 2016-06-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against streptococcus pneumoniae serotype 4
BR112018012310A2 (pt) 2015-12-17 2018-12-04 Max Planck Gesellschaft sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina
WO2017220753A1 (en) * 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition

Also Published As

Publication number Publication date
SG11201803881RA (en) 2018-06-28
WO2017103211A1 (en) 2017-06-22
JP2019504017A (ja) 2019-02-14
IL259289A (en) 2018-07-31
CN108367059B (zh) 2022-10-11
MX2018007367A (es) 2018-08-14
IL259289B (en) 2019-12-31
CN108367059A (zh) 2018-08-03
EP3331556B1 (en) 2018-10-31
HK1256630B (zh) 2020-05-22
EP3331556B8 (en) 2019-02-27
US20200016257A1 (en) 2020-01-16
KR20180091921A (ko) 2018-08-16
PH12018501205A1 (en) 2019-02-11
JP6630440B2 (ja) 2020-01-15
US10864261B2 (en) 2020-12-15
AU2016372547A1 (en) 2018-07-05
MX371087B (es) 2020-01-16
EP3331556A1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
ECSP17043316A (es) Polvo de coleópteros
BR112018012310A2 (pt) sacarídeo, método de síntese de sacarídeo, intermediário, conjugado e vacina
BR112017013891A2 (pt) composições imunogênicas para uso em vacinas pneumocócicas
ECSP17043318A (es) Composición que contiene quitina y proteínas digeribles
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016013493A2 (pt) molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
BR112012031183A2 (pt) líquidos nutricionais substancialmente claros compreendendo proteína de cálcio hmb e solúvel
BR112013018642A2 (pt) vacinas e composições contra streptococcus pneumoniae
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112019005329A2 (pt) composições de oligossacarídeos de leite humano purificadas
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
BR112015016817A8 (pt) métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112016000210A2 (pt) Vacinas sintéticas contra streptococcus pneumoniae tipo 1
BR112017026834A2 (pt) composição compreendendo vitaminas b e vitaminas c e seu uso
WO2016198170A8 (en) Vaccines against streptococcus pneumoniae serotype 5
BR112018002140A2 (pt) USO DE MARCADORES MOLECULARES IL-3, IL-33 e IL-12p40 PARA CARACTERIZAR ASGRAVIDADES DAS INFECÇÕES RESPIRATÓRIAS POR VÍRUS RESPIRATÓRIO SINCITIAL E METAPNEUMOVÍRUS HUMANO
BR112016017242A2 (pt) Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1
MX2018008415A (es) Cepas de vacuna de brachyspira hyodysenteriae.
BR112018002107A2 (pt) resposta imune potencializada em espécies suínas
BR112017004356A2 (pt) antígenos de streptococcus agalactiae associados a cepas virulentais em peixes
BR112021024189A2 (pt) Método para sintetizar um polissacarídeo de ramnose, produto, polissacarídeos estreptocócico sintético e de ramnose estreptocócico sintético, glicoconjugados estreptocócico e de ramnose estreptocócico, composição ou vacina imunogênica, célula hospedeira bacteriana, e, kit de partes

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]